Minerva Neurosciences, Inc. (NASDAQ:NERV) Short Interest Down 54.1% in March

Minerva Neurosciences, Inc. (NASDAQ:NERV) was the recipient of a large decrease in short interest during the month of March. As of March 15th, there was short interest totalling 26,100 shares, a decrease of 54.1% from the February 28th total of 56,900 shares. Currently, 0.5% of the company’s stock are sold short. Based on an average trading volume of 42,400 shares, the days-to-cover ratio is presently 0.6 days.

Minerva Neurosciences Price Performance

NERV stock remained flat at $1.81 during midday trading on Friday. The company’s stock had a trading volume of 10,508 shares, compared to its average volume of 28,423. The stock’s fifty day moving average price is $1.93 and its 200 day moving average price is $2.24. The stock has a market cap of $12.66 million, a price-to-earnings ratio of -4.11 and a beta of 0.10. Minerva Neurosciences has a 12 month low of $1.42 and a 12 month high of $3.69.

Minerva Neurosciences (NASDAQ:NERV) last posted its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.05) by $0.49. As a group, analysts anticipate that Minerva Neurosciences will post -0.3 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on NERV. HC Wainwright reaffirmed a “neutral” rating and set a $5.00 price target on shares of Minerva Neurosciences in a research report on Wednesday, February 26th. StockNews.com began coverage on Minerva Neurosciences in a report on Wednesday. They issued a “sell” rating for the company.

Institutional Investors Weigh In On Minerva Neurosciences

An institutional investor recently raised its position in Minerva Neurosciences stock. Citadel Advisors LLC raised its holdings in shares of Minerva Neurosciences, Inc. (NASDAQ:NERV) by 49.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,764 shares of the biopharmaceutical company’s stock after acquiring an additional 8,525 shares during the period. Citadel Advisors LLC owned approximately 0.37% of Minerva Neurosciences worth $57,000 as of its most recent SEC filing. Institutional investors own 34.56% of the company’s stock.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.